Connecticut plans to authorize generic GLP-1 drugs for HUSKY Health members

On April 2, 2025, the Connecticut State Legislature introduced Substitute Bill No. 11, aimed at enhancing healthcare accessibility and affordability for residents. The bill encompasses several key provisions that address critical issues in the state's health insurance landscape.

One of the primary components of the bill mandates that any stop-loss insurance policy associated with self-funded employee health benefit plans must either provide coverage for essential health benefits as defined by the Affordable Care Act or meet specific financial thresholds. These thresholds include a minimum individual attachment point of $75,000 and an aggregate attachment point of $250,000. This provision seeks to ensure that employees have access to comprehensive health coverage while also protecting employers from excessive financial risk.

Another significant aspect of the bill focuses on prescription drug affordability, particularly for glucagon-like peptide (GLP-1) medications used to treat obesity and diabetes. The bill requires the Commissioner of Social Services to petition the federal Department of Health and Human Services for authorization to procure generic, lower-cost versions of these drugs. Upon approval, the state plans to contract with manufacturers to supply these medications to members of the HUSKY Health program, thereby aiming to reduce costs and improve access for vulnerable populations.

The bill also establishes an advisory committee tasked with exploring additional strategies to enhance access to cost-effective prescription drugs. This committee is expected to report its findings and recommendations to the General Assembly by the end of 2025.

Debate surrounding Senate Bill 11 has highlighted concerns regarding the potential impact on insurance premiums and the overall healthcare market. Proponents argue that the bill will significantly lower costs for consumers and improve health outcomes, while opponents caution that the financial implications for employers could lead to increased premiums or reduced coverage options.

The economic implications of this bill are noteworthy, as it seeks to address rising healthcare costs that have burdened both individuals and businesses in Connecticut. By promoting the use of generic medications and ensuring comprehensive coverage, the bill aims to alleviate some of the financial pressures associated with healthcare.

As the legislative process unfolds, the future of Senate Bill 11 will depend on ongoing discussions and potential amendments. If passed, it could mark a significant step toward improving healthcare access and affordability in Connecticut, setting a precedent for similar initiatives in other states.